Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study.

ABSTRACT:

Background

There is a pressing need for new classes of treatment for psychosis. A key therapeutic target for novel compounds is the NMDA receptor, which may be modulated by nitric oxide donors such as sodium nitroprusside (SNP). Recent studies of SNP in patients with psychosis have mixed results, and the drug has to be administered intravenously. Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor, and can be given orally.

Aims

We explored the safety and potential effects of GTN in unmedicated patients with a first episode of psychosis.

Methods

This was a single-centre, randomised, double-blind, placebo-controlled trial from December 2016 to April 2019 (ClinicalTrials.gov identifier: NCT02906553). Patients received

SUBMITTER: Merritt K 

PROVIDER: S-EPMC7376621 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature